Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  atrasentan hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
A Long Term Safety Study With Atrasentan
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M01-304, NCT00127478
Phase III Randomized Study of Atrasentan in Patients With Non-Metastatic Hormone-Refractory Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 19 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABBOTT-M00-244, ABBOTT-ABT-627, UCLA-0107068
Phase III Randomized Study of Atrasentan in Patients With Metastatic Hormone-Refractory Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 19 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABBOTT-M00-211, ABBOTT-627, UCLA-010506301
Atrasentan in Treating Patients With Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 19 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000257127, ABBOTT-M00-258, UCLA-0202002, NCI-G02-2110, NCT00046943
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000439434, S0421, U10CA032102, SWOG-S0421, NCT00134056
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
Phase: Phase II
Type: Treatment
Status: Completed
Age: 19 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M01-366, NCT00038662
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069382, E6800, ECOG-E6800, NCT00039429
Phase I Study of Atrasentan in Patients With Progressive or Recurrent Malignant Glioma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTT-2008, JHOC-NABTT-2008, NCT00017264
Start Over